Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
HIV InfectionPneumococcal Infections
Interventions
BIOLOGICAL

pneumococcal conjugate 13 valent vaccine

"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."

Trial Locations (2)

53100

UOC Malattie Infettive Universitarie, Policlinico Le Scotte, Siena

00168

Istituto di Clinica delle Malattie Infettive, Policlinico Gemelli, Roma

All Listed Sponsors
collaborator

Ministry of Education, Universities and Research, Italy

OTHER

lead

University of Siena

OTHER

NCT02123433 - Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults | Biotech Hunter | Biotech Hunter